ArteriaL Fluorescence Angiography for Peripheral Arterial Disease (ALFAPAD) Study

ArteriaL Fluorescence Angiography for Peripheral Arterial Disease (ALFAPAD) Study - ALFAPAD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53719

Enrollment

Registered

2023-02-24

Start date

2024-02-14

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral arterial disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Peripheral arterial disease patients with a Rutherford classification of 4, 5 or 6

Exclusion criteria

Exclusion criteria: Severely impaired renal function (eGFR

Design outcomes

Primary

Measure	Time frame
1. Near-infrared video-data and the quantified parameters based on intensity-time curves of ALFA measurements. 2. Clinical improvement; wound healing (WIFI classification, amputation and walking distance (Rutherford classification) after 6 months.	—

Secondary

Measure	Time frame
1. Technical success of ALFA measurements. 2. Technical success of the PAD treatment procedure. 3. Quantified parameters extracted from postoperative intravenous FA measurements. 4. Number of adverse events.	—

Countries

Netherlands

Outcome results